Intraperitoneal administration of an anti-CTGF monoclonal antibody reduces elevated CTGF levels, accumulation of myofibroblasts, number of CD31-positive vessels, and VEGF-A expression in a murine peritoneal fibrosis model exposed to chlorhexidine gluconate [92]. Here, VEGFA is linked to Peritoneal Fibrosis.